Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 1.00 |
| ▸ | CDC25B | P30305 | 4/20 | 1.00 |
| ▸ | AURKA | O14965 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | RECQL | P46063 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | P4HB | P07237 | 3/20 | 1.00 |
| ▸ | TOP1 | P11387 | 3/20 | 1.00 |
| ▸ | TRPA1 | O75762 | 2/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Juglone SCHEMBL34185 | 1.00 | MAPT (1.00) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL29500185 | 1.00 | MAPT (1.00) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL17888856 | 0.98 | MAPT (0.96) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL14246054 | 0.96 | MAPT (0.92) | MAPTCDC25BAURKAKDM4ERECQL | |
| Anthraquinone SCHEMBL14245036 | 0.92 | MAPT (0.85) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL9476381 | 0.92 | MAPT (0.85) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL27828137 | 0.92 | MAPT (0.85) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL2720570 | 0.92 | MAPT (0.85) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL25330089 | 0.90 | MAPT (0.81) | MAPTCDC25BAURKAKDM4ERECQL | |
| Juglone SCHEMBL11781111 | 0.90 | MAPT (0.81) | MAPTCDC25BAURKAKDM4ERECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11883413-B2 | Inhibition of thymine DNA glycosylase in the treatment of cancer | INSTITUT CURIE (FR) | 2024-01-30 | — | — | US | disclosed |
| US-20220054500-A1 | Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer | INSTITUT CURIE (FR) | 2022-02-24 | — | — | US | disclosed |
| US-11077121-B2 | Inhibition of thymine DNA glycosylase in the treatment of cancer | INSTITUTE FOR CANCER RESEARCH (US) | 2021-08-03 | — | — | US | disclosed |
| EP-3280402-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | Biomendics LLC (US) | 2018-02-14 | — | — | EP | disclosed |
| WO-2016164531-A2 | FORMULATION AND PROCESS FOR MODULATING WOUND HEALING | BioMendics, LLC (US) | 2016-10-13 | — | — | WO | disclosed |
| US-20160199381-A1 | Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer | INSTITUT DE GENETIQUE ET DE BIOLOGIE MOLECULAIRE ET CELLULAIRE (FR) | 2016-07-14 | — | — | US | disclosed |
| WO-2015104713-A1 | COLORING COMPOSITIONS AND METHODS | Ramot at Tel- Aviv University Ltd. (IL) | 2015-07-16 | — | — | WO | disclosed |
| EP-2646045-A1 | CHEMICAL AND RNAI SUPPRESSORS OF NEUROTOXICITY IN HUNTINGTON'S DISEASE | Massachusetts Institute Of Technology (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130224286-A1 | METHODS AND COMPOSITIONS FOR TREATING POX VIRUS INFECTIONS | HUEGIN AMBROS (CH) | 2013-08-29 | — | — | US | disclosed |
| WO-2012075408-A1 | CHEMICAL AND RNAI SUPPRESSORS OF NEUROTOXICITY IN HUNTINGTON'S DISEASE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220054500-A1 | Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer | UNG, MPG, TYMP | MAPT 1950/4885CDC25B 170/4885AURKA 969/4885 |
| US-11077121-B2 | Inhibition of thymine DNA glycosylase in the treatment of cancer | UNG, MPG, TYMP | MAPT 1950/4885CDC25B 170/4885AURKA 969/4885 |
| US-20160199381-A1 | Inhibition of Thymine DNA Glycosylase in the Treatment of Cancer | UNG, MPG, TYMP | MAPT 1950/4885CDC25B 170/4885AURKA 969/4885 |
| US-11883413-B2 | Inhibition of thymine DNA glycosylase in the treatment of cancer | UNG, MPG, TYMP | MAPT 1950/4885CDC25B 170/4885AURKA 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.